Recent Quotes (30 days)

You have no recent quotes
chg | %

Knight Therapeutics Inc  

(Public, CVE:GUD)   Watch this stock  
Find more results for GUD
Delayed:   3:59PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 3.51 - 7.24
Open     -
Vol / Avg. 0.00/822,875.00
Mkt cap 138.83M
P/E     -
Div/yield     -
EPS 0.00
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 8153.04% -
Operating margin -23248.26% -
EBITD margin - -
Return on average assets 0.86% -
Return on average equity 0.87% -
CDP Score - -


Suite 102, 6111 Royalmount Avenue
+1-514-3401112 (Phone)
+1-514-3444675 (Fax)

Website links


Knight Therapeutics Inc. (Knight) is a specialty pharmaceutical company. The Company is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products. The Company�s product pipeline consists of the product Impavido (miltefosine), an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Impavido is an oral agent indicated for the treatment of visceral and cutaneous leishmaniasis and was included in the World Health Organization (WHO) essential medicines list as an anti-leishmaniasis medicine.